Lithium Carbonate ( DrugBank: Lithium carbonate, Carbonate )


5 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症10
13多発性硬化症/視神経脊髄炎1
17多系統萎縮症2
18脊髄小脳変性症(多系統萎縮症を除く。)2
127前頭側頭葉変性症1

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000579-19-ES
(EUCTR)
04/04/202202/11/2021An international multi-center clinical trial to investigate the efficacy of multiple drug compounds in patients with Amyotrophic Lateral Sclrerosis (ALS).A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) - MAGNET Amyotrophic Lateral Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Lithium Carbonate
INN or Proposed INN: Lithium carbonate
Other descriptive name: LITHIUM CARBONATE
Stichting TRICALS FoundationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
171Phase 3Belgium;Spain;Ireland;Australia;Netherlands;United Kingdom;Sweden
2EUCTR2020-000579-19-NL
(EUCTR)
25/06/202129/03/2021An international multi-center clinical trial to investigate the efficacy of multiple drug compounds in patients with Amyotrophic Lateral Sclrerosis (ALS).A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) - MAGNET Amyotrophic Lateral Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Lithium Carbonate
INN or Proposed INN: Lithium carbonate
Other descriptive name: LITHIUM CARBONATE
Stichting TRICALS FoundationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
171Phase 3Spain;Belgium;Ireland;Australia;Netherlands;United Kingdom;Sweden
3EUCTR2008-006722-34-IT
(EUCTR)
23/06/200911/12/2008Multicentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS - RCT ALS LithiumMulticentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS - RCT ALS Lithium Amyotrophic Lateral Sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: CARBOLITHIUM
INN or Proposed INN: Lithium
ISTITUTO SUPERIORE DI SANITA`NULLNot RecruitingFemale: yes
Male: yes
Italy
4EUCTR2008-006224-61-ES
(EUCTR)
12/06/200904/05/2009Ensayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral AmiotróficaEnsayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral Amiotrófica Esclerosis Lateral Amiotrófica
MedDRA version: 9;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: PLENUR
INN or Proposed INN: LITIO CARBONATO
Other descriptive name: LITHIUM CARBONATE
Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNULLNot RecruitingFemale: yes
Male: yes
Spain
5NCT00925847
(ClinicalTrials.gov)
June 200919/6/2009Effect of Lithium Carbonate in Patients With Amyotrophic Lateral SclerosisOpen Multicenter Study of Lithium in Patients With Amyotrophic Lateral Sclerosis LISLAAmyotrophic Lateral SclerosisDrug: lithiumAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/ABoth23Phase 2France
6EUCTR2008-005106-38-ES
(EUCTR)
14/05/200926/02/2009ENSAYO CLÍNICO RANDOMIZADO DOBLE CIEGO DE CARBONATO DE LITIO COMO TERAPIA DE ASOCIACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA (FASE II) - LIELAENSAYO CLÍNICO RANDOMIZADO DOBLE CIEGO DE CARBONATO DE LITIO COMO TERAPIA DE ASOCIACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA (FASE II) - LIELA Esclerosis Lateral Amiotrofica
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: PLENUR
INN or Proposed INN: LITIO CARBONATO
Other descriptive name: LITHIUM CARBONATE
Lucia Galan Hospital Clinico San CarlosNULLNot RecruitingFemale: yes
Male: yes
280Spain
7EUCTR2008-006891-31-GB
(EUCTR)
17/02/200928/07/2010A randomised placebo-controlled trial of Lithium carbonate in Amyotrophic Lateral Sclerosis (LiCALS) - LiCALSA randomised placebo-controlled trial of Lithium carbonate in Amyotrophic Lateral Sclerosis (LiCALS) - LiCALS Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: Lithium Apogepha
Product Name: Lithium Carbonate
Other descriptive name: LITHIUM CARBONATE
Trade Name: Lithium Carbonate
Product Name: Lithium Carbonate
Other descriptive name: LITHIUM CARBONATE
Trade Name: Lithium Citrate
Product Name: Lithium Citrate
Other descriptive name: LITHIUM CITRATE
King's College LondonNULLNot RecruitingFemale: yes
Male: yes
220Phase 4United Kingdom
8NCT00818389
(ClinicalTrials.gov)
January 20096/1/2009Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: Lithium Carbonate;Drug: Riluzole;Drug: placeboMassachusetts General HospitalALS Association;ALS Society of Canada;National Institute of Neurological Disorders and Stroke (NINDS);University of Toronto;State University of New York - Upstate Medical University;Columbia University;University of KentuckyTerminated18 YearsN/AAll84Phase 2/Phase 3United States;Canada
9EUCTR2008-002110-22-NL
(EUCTR)
16/09/200805/08/2008A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALSA randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALS Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthood. Muscle weakness gradually progresses. Approximately 50% of patients die within 3 years after onset of symptoms, usually as the result of respiratory failure. To date, only one drug, i.e. riluzole, has proven to extend survival in patients with ALS, but only by approximately 3 to 6 months.
MedDRA version: 9.1;Level: LLT;Classification code 10052889;Term: ALS
Trade Name: Lithiumcarbonaat 400 PCH tabletten
Product Name: Lithiumcarbonaat
Other descriptive name: LITHIUM CARBONATE
Prof. dr L.H. van den Berg, UMC-UtrechtNULLNot RecruitingFemale: yes
Male: yes
Netherlands
10NCT00790582
(ClinicalTrials.gov)
May 200812/11/2008A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: lithium carbonateForbes Norris MDA/ALS Research CenterMuscular Dystrophy AssociationCompleted21 Years80 YearsAll109Phase 2United States

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01259388
(ClinicalTrials.gov)
May 201110/12/2010A Pilot Study of Lithium in Progressive Multiple SclerosisA Pilot Trial of Lithium in Progressive Multiple SclerosisMultiple SclerosisDrug: Lithium CarbonateVA Office of Research and DevelopmentNULLCompleted30 Years65 YearsAll23Phase 1/Phase 2United States

17. 多系統萎縮症


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-016377-15-IT
(EUCTR)
26/10/200926/10/2009DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSADOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSA Muliple system atrophy
MedDRA version: 9.1;Level: HLT;Classification code 10008028
Trade Name: LITIO CARBONATO
INN or Proposed INN: LITHIUM CARBONATE
UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO IINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
2NCT00997672
(ClinicalTrials.gov)
October 200916/10/2009Lithium in Multiple System AtrophyA Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Tolerability of Lithium in Multiple System Atrophy.Multiple System AtrophyDrug: Lithium Carbonate;Drug: PlaceboFederico II UniversityNULLTerminated18 Years80 YearsAll10Phase 2Italy

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 76 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01096082
(ClinicalTrials.gov)
May 201129/3/2010Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3Spinocerebellar Ataxia Type 3;Machado Joseph DiseaseDrug: Lithium Carbonate;Drug: PlaceboHospital de Clinicas de Porto AlegreNULLCompleted16 Years80 YearsBoth62Phase 2/Phase 3Brazil
2NCT00683943
(ClinicalTrials.gov)
May 18, 200822/5/2008Lithium Treatment for Patients With Spinocerebellar Ataxia Type IPilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1)Spinocerebellar Ataxia Type IDrug: Lithium CarbonateNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted18 Years65 YearsAll13Phase 1United States

127. 前頭側頭葉変性症


臨床試験数 : 90 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02862210
(ClinicalTrials.gov)
January 27, 20177/8/2016Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal DementiaLow-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal DementiaFrontotemporal Dementia (FTD)Drug: Lithium Carbonate;Drug: PlaceboColumbia UniversityAlzheimer's Drug Discovery FoundationCompleted40 Years85 YearsAll17Phase 2United States